2023 Fiscal Year Final Research Report
Tumor targeted oligonucleotide therapy via lymphatic route for achievement of complete cure from relapsed malignant lymphoma
| Project/Area Number |
21K07224
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
|---|
| Research Institution | Josai University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
安藤 祐介 城西大学, 薬学部, 助教 (10805881)
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | リンパ管 / 悪性リンパ腫 / B細胞 / DDS / 抗体医薬 / 核酸医薬 |
|---|
| Outline of Final Research Achievements |
In the treatment of malignant lymphoma, several therapies, such as radiation therapy, combination chemotherapy with molecular targeted drugs, hematopoietic stem cell transplantation therapy, and CAR-T therapy are being used. However, lymphomas are still prone to systemic metastasis via blood vessels and lymphatic vessels, it is required to complete prevention of relapse after remission.
In this study, with the ultimate goal of creating a novel therapeutic agent for the complete cure of recurrent malignant lymphoma, we created a prototype of an oligonucleotide medicine that has the ability to transit to the lymphatic system and retains the carriers to target B-cell tumors and build a platform including the elucidation of the lymphatic system.
|
| Free Research Field |
免疫学
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究における悪性リンパ腫治療薬開発では、既存の療法で必要な複雑な治療ステップを必要とせず、化学療法を用いないことから、副作用や有害事象の回避や軽減が可能である。また経腸薬物送達システムを基盤とすることから、経腸システムを発展させ、将来的には経口服用も可能となる可能性が高い為、患者のQOL向上に大きく貢献することが可能となる。また、リンパ管経路は血管経路に比較して機序解明が遅れていたが、本研究の開発に伴い、新しい知見が得られ、学術的な貢献となる。総合的に本研究の成果は、再発性悪性リンパ腫の完全根治の新規治療法開発の基盤となる。
|
